Form 4: Cytek Biosciences Director Michael Holder Reports Stock Transactions

Director Michael Holder of Cytek Biosciences reported the vesting of restricted stock units and subsequent disposal of shares on November 18, 2024.

Summary

• Michael Holder, a director at Cytek Biosciences, reported a transaction involving restricted stock units (RSUs).
• On November 18, 2024, 2,181 RSUs vested, each representing one share of Cytek's common stock.
• Following the vesting, 2,181 shares were disposed of.
• After these transactions, Holder directly owns 22,543 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a standard stock transaction by a company director. It does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the stock ownership of company directors.

Comparison to Industry Standards

• The vesting schedule of the restricted stock units is typical for equity compensation plans in the biotech industry.
• The reporting of these transactions via SEC Form 4 is standard practice for publicly traded companies, such as Cytek Biosciences, and is similar to filings made by directors at companies like Bio-Rad Laboratories and Illumina.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine vesting and disposal of shares by a director.

Key Dates

Keywords

Cytek Biosciences, Director, Michael Holder, Restricted Stock Units, RSU, Stock Transaction, Vesting, SEC Form 4, Insider Trading